TY - JOUR
T1 - Rare benign and malignant testicular lesions
T2 - Histopathology and management
AU - Kern, Sean Q.
AU - Speir, Ryan W.
AU - Akgul, Mahmut
AU - Cary, Clint
N1 - Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose of reviewThe presence of vascular solid tumors within the testicle is considered to be malignant until proven otherwise. However, it is prudent for clinicians to be aware of rare benign and malignant intratesticular lesions as management can differ from the established treatment algorithms for germ-cell tumors.Recent findingsUtilizing certain histopathologic findings can assist with the diagnosis of rare testis tumors. Often times the tumor subtypes are an important consideration in the grading and classification of the disease, which drives management. The multidisciplinary management of rare malignant testis tumors at an experienced center seems to provide optimal patient outcomes. Regardless of the primary treatment, prolonged follow-up for sex cord stromal tumors and other rare testis malignancies is advocated due to the delayed metastatic potential.SummaryThe clinical presentation of rare benign and malignant testis tumors is often similar to that of germ-cell tumors. Likewise, imaging characteristics are also often indistinguishable. However, the management of these rare tumors is often different from the well established treatment algorithms of germ-cell tumors. To that end, it is important for the practicing urologist to be familiar with the current principles of these tumor characteristics and the management.
AB - Purpose of reviewThe presence of vascular solid tumors within the testicle is considered to be malignant until proven otherwise. However, it is prudent for clinicians to be aware of rare benign and malignant intratesticular lesions as management can differ from the established treatment algorithms for germ-cell tumors.Recent findingsUtilizing certain histopathologic findings can assist with the diagnosis of rare testis tumors. Often times the tumor subtypes are an important consideration in the grading and classification of the disease, which drives management. The multidisciplinary management of rare malignant testis tumors at an experienced center seems to provide optimal patient outcomes. Regardless of the primary treatment, prolonged follow-up for sex cord stromal tumors and other rare testis malignancies is advocated due to the delayed metastatic potential.SummaryThe clinical presentation of rare benign and malignant testis tumors is often similar to that of germ-cell tumors. Likewise, imaging characteristics are also often indistinguishable. However, the management of these rare tumors is often different from the well established treatment algorithms of germ-cell tumors. To that end, it is important for the practicing urologist to be familiar with the current principles of these tumor characteristics and the management.
KW - Leydig cell
KW - Sertoli cell
KW - granulosa cell
KW - sarcoma
KW - testicular neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85081147278&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000715
DO - 10.1097/MOU.0000000000000715
M3 - Review article
C2 - 31922967
AN - SCOPUS:85081147278
SN - 0963-0643
VL - 30
SP - 235
EP - 244
JO - Current Opinion in Urology
JF - Current Opinion in Urology
IS - 2
ER -